CLINICAL_TRIALS
trial_result
· 2024-09-20
Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy [Phase 1]
Summary
Phase 1 study evaluating PF-06939926 gene therapy in Duchenne muscular dystrophy was terminated. Results from the study have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: TERMINATED | Results posted: 2024-09-20